Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Accumulated Expenses (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Accumulated Expenses for 13 consecutive years, with $64.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses rose 424.88% year-over-year to $64.5 million, compared with a TTM value of $64.5 million through Sep 2025, up 424.88%, and an annual FY2024 reading of $64.1 million, up 403.91% over the prior year.
  • Accumulated Expenses was $64.5 million for Q3 2025 at Tandem Diabetes Care, up from $13.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $64.5 million in Q3 2025 and bottomed at $5.1 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $24.8 million, with a median of $13.7 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses surged 977.9% in 2021, then tumbled 83.27% in 2022.
  • Year by year, Accumulated Expenses stood at $51.6 million in 2021, then crashed by 81.39% to $9.6 million in 2022, then surged by 32.63% to $12.7 million in 2023, then skyrocketed by 403.91% to $64.1 million in 2024, then grew by 0.51% to $64.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for TNDM at $64.5 million in Q3 2025, $13.8 million in Q2 2025, and $13.7 million in Q1 2025.